Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ECIANASDAQ:IRIXNASDAQ:NXGLNASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECIAEncision$0.37$0.40$0.12▼$0.57$4.45M0.544,929 shsN/AIRIXIRIDEX$0.94+1.1%$1.04$0.78▼$2.41$15.78M0.6149,396 shs27,516 shsNXGLNEXGEL$2.21-7.5%$2.49$1.84▼$5.10$16.92M0.5269,546 shs48,567 shsXAIRBeyond Air$0.18-8.4%$0.20$0.16▼$1.49$15.83M0.231.29 million shs4.02 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECIAEncision0.00%-0.27%-10.86%-21.67%-25.12%IRIXIRIDEX-1.58%-5.11%-19.12%-4.11%-56.74%NXGLNEXGEL+5.75%+4.37%-12.13%-14.03%+7.17%XAIRBeyond Air+1.68%+6.38%+2.56%-20.19%-84.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationECIAEncisionN/AN/AN/AN/AN/AN/AN/AN/AIRIXIRIDEX0.5521 of 5 stars0.03.00.00.02.21.70.0NXGLNEXGEL1.4126 of 5 stars0.05.00.00.02.52.50.0XAIRBeyond Air4.4717 of 5 stars3.54.00.03.52.22.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceECIAEncision 0.00N/AN/AN/AIRIXIRIDEX 0.00N/AN/AN/ANXGLNEXGEL 0.00N/AN/AN/AXAIRBeyond Air 3.00Buy$1.50718.33% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookECIAEncision$6.59M0.67N/AN/A$0.14 per share2.67IRIXIRIDEX$48.80M0.32N/AN/A$0.59 per share1.59NXGLNEXGEL$10.23M1.65N/AN/A$0.90 per share2.46XAIRBeyond Air$3.02M5.24N/AN/A$0.27 per share0.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateECIAEncision-$690K-$0.04N/A∞N/A-8.96%-32.90%-15.51%7/14/2025 (Estimated)IRIXIRIDEX-$9.57M-$0.43N/A∞N/A-22.79%-192.95%-33.97%8/6/2025 (Estimated)NXGLNEXGEL-$3.16M-$0.45N/A∞N/A-52.60%-71.19%-34.79%N/AXAIRBeyond Air-$60.24M-$1.06N/AN/AN/A-1,730.00%-226.01%-109.75%6/17/2025 (Estimated)Latest ECIA, NXGL, XAIR, and IRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/17/2025Q4 2025XAIRBeyond Air-$0.14N/AN/AN/A$1.39 millionN/A5/13/2025Q1 2025IRIXIRIDEX-$0.10-$0.10N/A-$0.10$12.10 million$11.90 million5/13/2025Q1 2025NXGLNEXGEL-$0.10-$0.09+$0.01-$0.09$2.73 million$2.81 million3/27/2025Q4 2024IRIXIRIDEX-$0.05-$0.05N/A-$0.05$12.80 million$12.70 million3/24/2025Q4 2024NXGLNEXGEL-$0.10-$0.08+$0.02-$0.11$2.99 million$3.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthECIAEncisionN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/ANXGLNEXGELN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioECIAEncision0.111.670.98IRIXIRIDEX0.551.540.85NXGLNEXGEL0.191.510.93XAIRBeyond AirN/A3.563.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipECIAEncision8.20%IRIXIRIDEX20.10%NXGLNEXGEL2.21%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipECIAEncision36.75%IRIXIRIDEX7.40%NXGLNEXGEL20.55%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableECIAEncision3011.88 million7.51 millionNot OptionableIRIXIRIDEX12016.79 million15.42 millionOptionableNXGLNEXGEL107.66 million5.10 millionNot OptionableXAIRBeyond Air7086.37 million54.97 millionOptionableECIA, NXGL, XAIR, and IRIX HeadlinesRecent News About These CompaniesBeyond Air (XAIR) to Release Quarterly Earnings on TuesdayJune 10 at 1:30 AM | americanbankingnews.comBeyond Oil Issues Clarification Regarding Previous German-Language Media ActivitiesJune 3, 2025 | globenewswire.comBeyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and WebcastMay 20, 2025 | globenewswire.comBeyond Air granted U.S. patent for gaseous nitric oxide deliveryApril 25, 2025 | markets.businessinsider.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Gets Patent for Lung Infection TreatmentApril 25, 2025 | marketwatch.comBeyond Air granted U.S. patent for treatment of NTM infections using gaseous Nitric OxideApril 25, 2025 | msn.comBeyond Air, Inc. Secures U.S. Patent for Novel Nitric Oxide Delivery Method in Treating NTM Lung InfectionsApril 24, 2025 | quiverquant.comBeyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismApril 23, 2025 | finanznachrichten.deNeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismApril 21, 2025 | globenewswire.comNeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory BoardApril 15, 2025 | globenewswire.comBeyond Air subsidiary granted orphan designation for Phelan-McDermid treatmentApril 15, 2025 | markets.businessinsider.comJonesTrading Sticks to Their Buy Rating for Beyond Air (XAIR)April 15, 2025 | markets.businessinsider.comBeyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at HomeApril 9, 2025 | globenewswire.comBeyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at HomeApril 9, 2025 | globenewswire.comBeyond Air subsidiary NeuroNOS announces publication of researchApril 2, 2025 | markets.businessinsider.comBeyond Air announces VUMC as first luminary siteApril 1, 2025 | markets.businessinsider.comBeyond Air Announces Vanderbilt University Medical Center as First Luminary SiteMarch 31, 2025 | globenewswire.comNeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism TherapyMarch 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in Value3 Overlooked Dividend Plays for Income in Volatile TimesBy Nathan Reiff | May 31, 2025View 3 Overlooked Dividend Plays for Income in Volatile TimesTaiwan Semiconductor: Time to Buy After Strong NVIDIA Results?By Gabriel Osorio-Mazilli | May 30, 2025View Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results?Canada Goose Soars 30%—Is This Rally Built to Last?By Thomas Hughes | May 21, 2025View Canada Goose Soars 30%—Is This Rally Built to Last?ECIA, NXGL, XAIR, and IRIX Company DescriptionsEncision OTCMKTS:ECIA$0.37 0.00 (0.00%) As of 06/11/2025Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.IRIDEX NASDAQ:IRIX$0.94 +0.01 (+1.08%) As of 03:58 PM EasternIRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.NEXGEL NASDAQ:NXGL$2.21 -0.18 (-7.53%) As of 03:59 PM EasternNEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.Beyond Air NASDAQ:XAIR$0.18 -0.02 (-8.35%) As of 04:00 PM EasternBeyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
